In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.
Albert Breer explains the supplemental draft process and shares some glowing recommendations from team evaluators: “His arm is electric.” ...
How much water will be available in Lake O’ the Pines if an extreme drought strikes, and how must the cities that depend on ...
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight ...
In older age, when retirement, illness, and bereavement can thin the ranks of casual acquaintances, that shared social world ...
The ERCHAM MK1 combines mouse and keyboard functions into a single unit. It features an optical sensor that enables ...
A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing ...
When the Supreme Court killed his favorite tariffs in February, President Donald Trump rolled out temporary import taxes to ...
The increasing frequency of emerging and re-emerging infectious diseases—driven by environmental change, globalisation, and intensified human–animal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results